Literature DB >> 9933148

Effects of retigabine (D-23129) on different patterns of epileptiform activity induced by 4-aminopyridine in rat entorhinal cortex hippocampal slices.

V Armand1, C Rundfeldt, U Heinemann.   

Abstract

The purpose of this study was to evaluate the effects of the new anticonvulsant drug N-(2-amino-4-[fluorobenzylaminol-phenyl) carbamic acid ethyl ester (retigabine, D-23129, ASTA Medica, Dresden, Germany) on different patterns of epileptiform activity induced by 4-aminopyridine (4AP) in rat entorhinal cortex hippocampal slices. Application of 4AP (100 microM) induced in entorhinal cortex two different types of epileptiform activities; seizure-like events (SLE) and interictal epileptiform discharges (IED). Bicuculline (10 microM) changed 4AP-induced SLE and IED to recurrent epileptiform discharges (RED). IED were isolated after blockade of the SLE by glutamate receptor antagonists for alpha-amino-3-hydroxy-5-methylisoxazole4-proprionic acid (AMPA) and N-methyl-D-aspartate (NMDA) receptors, i.e. 1,2,3,4 tetrahydro-6-nitro-2,3-dioxo-benzolflquinoxaline-7-sulfonamide (NBQX, 10 microM) and 2-amino-5-phosphonovaleric acid (APV, 30 microM). Anticonvulsant properties of retigabine were evaluated as effect on the frequency and amplitude of SLE, IED and RED. Retigabine suppressed all types of epileptiform events in a dose dependent and reversible manner. SLE were suppressed in 71.4 and 100% of slices by 5 and 10 microM, respectively. The frequency of IED was significantly reduced by 20 microM retigabine (40.9+/-24.5%) and IED were blocked completely by 50 microM retigabine. When IED were isolated by application of glutamate antagonists 20 microM retigabine was sufficient to block this activity completely. RED induced by combined application of bicuculline and 4AP were blocked in 71.4% of the tested slices with 100 microM retigabine. The frequency of the RED in the remaining slices was reduced by 96.1+/-6.1%. We conclude that retigabine acts on a large variety of different epileptiform activities in temporal lobe structures that are known to develop readily pharmacoresistant seizures.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9933148     DOI: 10.1007/pl00005320

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  12 in total

1.  The Sensorless Pore Module of Voltage-gated K+ Channel Family 7 Embodies the Target Site for the Anticonvulsant Retigabine.

Authors:  Ruhma Syeda; Jose S Santos; Mauricio Montal
Journal:  J Biol Chem       Date:  2015-12-01       Impact factor: 5.157

2.  Retigabine: has the orphan found a home?

Authors:  Elinor Ben-Menachem
Journal:  Epilepsy Curr       Date:  2007 Nov-Dec       Impact factor: 7.500

3.  Effects of retigabine on the neurodegeneration and extracellular glutamate changes induced by 4-aminopyridine in rat hippocampus in vivo.

Authors:  Gabriela Mora; Ricardo Tapia
Journal:  Neurochem Res       Date:  2005-12       Impact factor: 3.996

4.  KV7/M channels mediate osmotic modulation of intrinsic neuronal excitability.

Authors:  Anna Caspi; Felix Benninger; Yoel Yaari
Journal:  J Neurosci       Date:  2009-09-09       Impact factor: 6.167

Review 5.  Retigabine.

Authors:  Roger J Porter; Virinder Nohria; Chris Rundfeldt
Journal:  Neurotherapeutics       Date:  2007-01       Impact factor: 7.620

Review 6.  Novel medications for epilepsy.

Authors:  Cinzia Fattore; Emilio Perucca
Journal:  Drugs       Date:  2011-11-12       Impact factor: 9.546

7.  Antiepileptogenic and antiictogenic effects of retigabine under conditions of rapid kindling: an ontogenic study.

Authors:  Andréy Mazarati; Jim Wu; Don Shin; Young Se Kwon; Raman Sankar
Journal:  Epilepsia       Date:  2008-05-21       Impact factor: 5.864

8.  Isobolographic characterization of interactions of retigabine with carbamazepine, lamotrigine, and valproate in the mouse maximal electroshock-induced seizure model.

Authors:  Jarogniew J Luszczki; Jim Z Wu; Grzegorz Raszewski; Stanislaw J Czuczwar
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-09-05       Impact factor: 3.000

9.  The new KCNQ2 activator 4-Chlor-N-(6-chlor-pyridin-3-yl)-benzamid displays anticonvulsant potential.

Authors:  A Boehlen; M Schwake; R Dost; A Kunert; P Fidzinski; U Heinemann; C Gebhardt
Journal:  Br J Pharmacol       Date:  2013-03       Impact factor: 8.739

10.  Involvement of inward rectifier and M-type currents in carbachol-induced epileptiform synchronization.

Authors:  Mauro Cataldi; Gabriella Panuccio; Anna Cavaccini; Margherita D'Antuono; Maurizio Taglialatela; Massimo Avoli
Journal:  Neuropharmacology       Date:  2010-12-07       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.